PALSONIFY
paltusotine Small Molecule Target: SST2, somatostatin receptor 2
Crinetics Pharmaceuticals, Inc.
Most recent annual filing: 2026-02-15
Pipeline (7 active programs)
atumelnant
Small Molecule Target: ACTH receptor, MC2R, melanocortin receptor
CRN09682
Small Molecule Target: SST2, somatostatin receptor 2
- Neuroendocrine Tumors
- Undisclosed indication
Technology platforms
NDC
Non-peptide drug conjugate (NDC) platform linking SST2 agonists with cytotoxic payloads via cleavable linkers for targeted delivery to SST2-expressing tumor cells; focus on neuroendocrine tumors and other SST2-positive solid tumors including SCLC, meningioma, head and neck cancer, and breast cancer
Targets: SST2, somatostatin receptor 2
Biotech Distilled coverage (4)
- 2026-05-09 UPDATE: Crinetics Pharmaceuticals (CRNX) — Sell-the-News Decoded 🔒 Paid
- 2026-05-08 UPDATE: Crinetics Pharmaceuticals (CRNX) — The Q1 Print Lands in the Bull Range 🔒 Paid
- 2026-04-28 UPDATE: Crinetics Pharmaceuticals (CRNX) — The EC Catalyst Hits 🔒 Paid
- 2026-04-02 Crinetics Pharmaceuticals (CRNX) - Scientific Deep Dive for Paltusotine and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.